Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazarotene vs Halobetasol Propionate for Scalp Psoriasis
NCT06015152Completed
- Sponsor
- Jinnah Postgraduate Medical Centre
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial of tazarotene in psoriasis, sponsored by Jinnah Postgraduate Medical Centre. Primary endpoint: Efficacy of Tazarotene 0.045% in Scalp Psoriasis at 2 weeks. Started Aug 2022; status: completed.
02
Drugs
tazarotene
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06015152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015152.